Link to COMPETE Clinical Trial

Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

Five employees about "Passion for Precision" at ITM.

See five employees talking about their work at ITM with five different views on “Passion for Precision”. A compilation.

Watch individual interviews >>

May 17, 2018

ITM Isotopen Technologien München AG chosen as a 2018 Red Herring Top 100 Europe Winner

Full releases >>

May 02, 2018

ITM Isotopen Technologien München AG unterzeichnet Charta der Vielfalt

Full releases >>

February 26, 2018

Endocyte and ITM announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

Full releases >>

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>